XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026)

XOMA Royalty's (XOMA) quarterly Income from Continuing Operations came in at 4465000.0 in Q1 2026, up 88.64% year-on-year from 2367000.0 in Q1 2025, and up 117.22% quarter-over-quarter from 25929000.0 in Q4 2025.

XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026) Analysis & Trends

XOMA Royalty has disclosed Income from Continuing Operations across 16 years of filings, most recently posting 4465000.0 for Q1 2026.

  • Income from Continuing Operations for Q1 2026 came in at 4465000.0, up 88.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 6046000.0 (up 67.45% YoY), and the FY2025 annual result was 320000.0, down 105.72% from the prior year.
  • Income from Continuing Operations came in at 4465000.0 for Q1 2026 at XOMA Royalty, up from 25929000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 14051000.0 in Q3 2025 to a low of 25929000.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 5787000.0 (2023), against an average of 5555000.0.
  • Across the five-year window, Income from Continuing Operations plunged 392.49% in 2023 and jumped 181.49% in 2025, its largest moves.
  • XOMA Royalty's Income from Continuing Operations stood at 6210000.0 in 2022, then slumped by 221.0% to 19934000.0 in 2023, then jumped by 149.09% to 9785000.0 in 2024, then slumped by 364.99% to 25929000.0 in 2025, then surged by 117.22% to 4465000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 4465000.0 (Q1 2026), 25929000.0 (Q4 2025), and 14051000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -2.97 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 30.80 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -14.46 Mn
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -3.40 Mn
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 1.03 Bn
9 Abivax 90.15 Bn 90.15 Bn - -56.48 Mn
10 XOMA Royalty 5.49 Mn -60.59 Mn - 4.47 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.47 Mn
Dec 31, 2025 -25.93 Mn
Sep 30, 2025 14.05 Mn
Jun 30, 2025 1.37 Mn
Mar 31, 2025 2.37 Mn
Dec 31, 2024 9.79 Mn
Sep 30, 2024 -17.24 Mn
Jun 30, 2024 -13.48 Mn
Mar 31, 2024 -10.56 Mn
Dec 31, 2023 -19.93 Mn
Sep 30, 2023 -5.79 Mn
Jun 30, 2023 -5.96 Mn
Mar 31, 2023 -10.17 Mn
Dec 31, 2022 -6.21 Mn
Sep 30, 2022 -4.37 Mn
Jun 30, 2022 -4.77 Mn
Mar 31, 2022 -2.07 Mn
Dec 31, 2021 29.86 Mn
Sep 30, 2021 -4.44 Mn
Jun 30, 2021 -2.24 Mn